Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYWG | ISIN: US76155X1000 | Ticker-Symbol: 42Z
Tradegate
26.06.25 | 20:38
32,000 Euro
-3,03 % -1,000
1-Jahres-Chart
REVOLUTION MEDICINES INC Chart 1 Jahr
5-Tage-Chart
REVOLUTION MEDICINES INC 5-Tage-Chart
RealtimeGeldBriefZeit
31,80032,40026.06.
31,60032,60026.06.

Aktuelle News zur REVOLUTION MEDICINES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiRevolution Medicines partners Royalty Pharma on $2bn funding6
DiRevolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds1
DiRoyalty Pharma Enters Into Upto $2 Bln Funding Deals With Revolution Medicines2
DiRevolution Medicines Partners Royalty Pharma On $2 Bln Flexible Funding-
DiRevolution Medicines dips 5%, gets $2B flexible funding2
DiRoyalty Pharma to provide Revolution Medicines up to $2 billion in funding1
DiRoyalty Pharma stellt Revolution Medicines bis zu 2 Milliarden US-Dollar bereit5
DiRevolution Medicines secures $2 billion funding deal with Royalty Pharma1
REVOLUTION MEDICINES Aktie jetzt für 0€ handeln
DiRoyalty Pharma plc: Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion1
DiRevolution Medicines, Inc.: Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with ...66Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debtCompany moving forward with independent global...
► Artikel lesen
MoRevolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib2
MoRevolution Medicines Says FDA Grants Breakthrough Therapy Designation For Daraxonrasib-
MoRevolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations674Breakthrough Therapy Designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma (PDAC) RASolute 302, a Phase 3 registrational...
► Artikel lesen
18.06.Revolution Medicines, Inc. - 8-K, Current Report2
14.05.Revolution Medicines startet Phase-3-Studie für Lungenkrebs-Medikament8
14.05.Revolution Medicines begins phase 3 trial for lung cancer drug1
07.05.Revolution Medicines, Inc. - 10-Q, Quarterly Report2
07.05.Revolution Medicines GAAP EPS of -$1.13 misses by $0.033
07.05.Revolution Medicines, Inc.: Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress145Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell...
► Artikel lesen
30.04.Revolution Medicines, Inc.: Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 20253
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1